RAMM Pharma Corp. (CSE:RAMM)

RAMM Pharma Statistics

Total Valuation

RAMM Pharma has a market cap or net worth of CAD 1.79 million. The enterprise value is 1.29 million.

Market Cap	1.79M
Enterprise Value	1.29M

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

RAMM Pharma has 119.39 million shares outstanding. The number of shares has increased by 0.01% in one year.

Current Share Class	119.39M
Shares Outstanding	119.39M
Shares Change (YoY)	+0.01%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	31.43%
Owned by Institutions (%)	0.01%
Float	81.87M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.47
PB Ratio	0.14
P/TBV Ratio	0.14
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.10
EV / Sales	0.34
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.80

Financial Position

The company has a current ratio of 1.49, with a Debt / Equity ratio of 0.00.

Current Ratio	1.49
Quick Ratio	0.82
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.02
Interest Coverage	-114.71

Financial Efficiency

Return on equity (ROE) is -69.77% and return on invested capital (ROIC) is -22.63%.

Return on Equity (ROE)	-69.77%
Return on Assets (ROA)	-20.42%
Return on Invested Capital (ROIC)	-22.63%
Return on Capital Employed (ROCE)	-55.77%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.18
Inventory Turnover	1.34

Taxes

In the past 12 months, RAMM Pharma has paid 12,666 in taxes.

Income Tax	12,666
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +50.00% in the last 52 weeks. The beta is 0.04, so RAMM Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.04
52-Week Price Change	+50.00%
50-Day Moving Average	0.01
200-Day Moving Average	0.01
Relative Strength Index (RSI)	52.50
Average Volume (20 Days)	46,040

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RAMM Pharma had revenue of CAD 3.78 million and -13.24 million in losses. Loss per share was -0.11.

Revenue	3.78M
Gross Profit	897,058
Operating Income	-6.92M
Pretax Income	-13.22M
Net Income	-13.24M
EBITDA	-6.37M
EBIT	-6.92M
Loss Per Share	-0.11

Balance Sheet

The company has 529,411 in cash and 27,788 in debt, giving a net cash position of 501,623 or 0.00 per share.

Cash & Cash Equivalents	529,411
Total Debt	27,788
Net Cash	501,623
Net Cash Per Share	0.00
Equity (Book Value)	12.41M
Book Value Per Share	0.10
Working Capital	1.23M

Cash Flow

In the last 12 months, operating cash flow was -1.58 million and capital expenditures -21,903, giving a free cash flow of -1.61 million.

Operating Cash Flow	-1.58M
Capital Expenditures	-21,903
Free Cash Flow	-1.61M
FCF Per Share	-0.01

Margins

Gross Margin	23.75%
Operating Margin	-183.22%
Pretax Margin	-350.16%
Profit Margin	n/a
EBITDA Margin	-168.79%
EBIT Margin	-183.22%
FCF Margin	n/a

Dividends & Yields

RAMM Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.01%
Shareholder Yield	-0.01%
Earnings Yield	-739.07%
FCF Yield	-89.63%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RAMM Pharma has an Altman Z-Score of -7.1 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.1
Piotroski F-Score	3